In the BioHarmony Drug Report Database

"Preview" Icon

Nilotinib

Tasigna (nilotinib) is a small molecule pharmaceutical. Nilotinib was first approved as Tasigna on 2007-10-29. It is used to treat myeloid leukemia accelerated phase and myeloid leukemia chronic-phase in the USA. It has been approved in Europe to treat bcr-abl positive chronic myelogenous leukemia. The pharmaceutical is active against tyrosine-protein kinase ABL1. In addition, it is known to target epithelial discoidin domain-containing receptor 1 and discoidin domain-containing receptor 2. Tasigna’s patents are valid until 2032-04-07 (FDA).

 

Trade Name

 

Tasigna
 

Common Name

 

nilotinib
 

ChEMBL ID

 

CHEMBL255863
 

Indication

 

bcr-abl positive chronic myelogenous leukemia, myeloid leukemia accelerated phase, myeloid leukemia chronic-phase
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Nilotinib structure rendering